 | I-Mab (NASDAQ:IMAB) Rating Lowered to Sell at Zacks Investment Research
marketbeat.com - June 10 at 10:11 PM |
 | I-Mab (NASDAQ:IMAB) Stock Price Down 2.8%
americanbankingnews.com - June 11 at 11:16 AM |
| I-Mab (NASDAQ:IMAB) Given New $90.00 Price Target at Cantor Fitzgerald
americanbankingnews.com - June 10 at 9:04 AM |
 | Calculating The Fair Value Of I-Mab (NASDAQ:IMAB)
finance.yahoo.com - June 8 at 1:40 PM |
| I-Mab (NASDAQ:IMAB) Sees Strong Trading Volume
americanbankingnews.com - June 4 at 12:21 PM |
| I-Mab (NASDAQ:IMAB) Shares Down 5.4%
americanbankingnews.com - June 2 at 12:36 PM |
| I-Mab (NASDAQ:IMAB) Earns Buy Rating from Analysts at Daiwa Capital Markets
americanbankingnews.com - June 2 at 8:54 AM |
| I-Mab to Hold Investor Call to Present In-Depth Phase 1 Clinical Data on Highly Differentiated CD73 Antibody Uliledlimab
finance.yahoo.com - June 2 at 8:13 AM |
| I-Mab Appoints Ruyi He and Rong Shao to Board of Directors
finance.yahoo.com - June 1 at 12:49 PM |
| I-Mab (NASDAQ:IMAB) Trading 8.9% Higher
americanbankingnews.com - May 27 at 11:57 AM |
|
| I-Mab (NASDAQ:IMAB) Sets New 52-Week High at $73.48
americanbankingnews.com - May 26 at 1:19 PM |
 | First Week of January 2022 Options Trading For I-Mab (IMAB)
nasdaq.com - May 21 at 3:19 PM |
| I-Mab (NASDAQ:IMAB) Shares Gap Up to $63.46
americanbankingnews.com - May 21 at 10:43 AM |
 | Why I-MAB's Stock Is Trading Higher Today
msn.com - May 20 at 7:01 PM |
| I-Mab (NASDAQ:IMAB) Shares Up 10.3%
americanbankingnews.com - May 20 at 11:38 AM |
| I-Mab Presents Phase 1 Data on Highly Differentiated CD73 Antibody Uliledlimab at ASCO 2021
finance.yahoo.com - May 19 at 6:48 PM |
| I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome
finance.yahoo.com - May 18 at 12:12 PM |
| I-Mab Added to MSCI China Index
finance.yahoo.com - May 13 at 8:40 AM |
| I-Mab Filed 2020 Annual Report on Form 20-F
finance.yahoo.com - April 28 at 9:33 AM |
| I-Mab's IL-6 Drug Hits Primary Endpoint Goal In Mid-Stage Ulcerative Colitis Study
finance.yahoo.com - April 26 at 2:00 PM |
| I-Mab Announces Positive Topline Phase 2 Results for Olamkicept in Ulcerative Colitis
finance.yahoo.com - April 26 at 9:00 AM |
| Read This Before Judging I-Mab's (NASDAQ:IMAB) ROE
nasdaq.com - April 22 at 7:45 AM |
| First Week of June 18th Options Trading For I-Mab (IMAB)
nasdaq.com - April 21 at 8:23 PM |
| I-Mab Announces Selected Poster Presentation of CD73 Antibody Uliledlimab at American Society of Clinical Oncology (ASCO) 2021 Annual Meeting
finance.yahoo.com - April 14 at 9:56 AM |
| Shanghai Genchem Co., Ltd. (Genechem) Announces Global Collaboration on Bispecific Antibodies
finance.yahoo.com - April 6 at 1:01 PM |
| I-Mab and ABL Bio Announce First Patient Dosed in Phase 1 Trial of Bispecific Antibody TJ-L14B/ABL503 in Patients with Advanced or Metastatic Solid Tumors
finance.yahoo.com - April 6 at 1:01 PM |
 | I-Mab collaborates with China's Genechem to develop bi-specific antibodies
seekingalpha.com - April 6 at 10:57 AM |
| Should I-Mab (NASDAQ:IMAB) Focus On Improving This Fundamental Metric?
finance.yahoo.com - March 31 at 1:49 PM |
| I-Mab and ABL Bio Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody TJ-CD4B/ABL111 in Patients with Advanced or Metastatic Solid Tumors
finance.yahoo.com - March 30 at 12:44 PM |
| I-Mab Reports Financial Results for Full Year of 2020 and Provides Business Updates
finance.yahoo.com - March 29 at 10:29 AM |
|
| I-Mab to Host 2021 R&D Day
finance.yahoo.com - March 24 at 9:33 AM |
| I-Mab Files Prospectus Supplement for Shelf Registration for Hillhouse
finance.yahoo.com - March 19 at 6:49 PM |
 | I-Mab Poised To Capitalize On Growing Oncology Sector, Needham Says In Bullish Initiation
markets.businessinsider.com - March 15 at 12:05 PM |
| I-Mab To Present Differentiated Mechanism of Action and Preclinical Data for Anti-CD73 Antibody Uliledlimab at 2021 American Association for Cancer Research Annual Meeting
finance.yahoo.com - March 11 at 12:10 PM |
| I-Mab Launches Discovery Initiative to Expand Transformational Immuno-Oncology Pipeline
markets.businessinsider.com - March 10 at 1:34 PM |
| I-Mab Launches Discovery Initiative to Expand Transformational Immuno-Oncology Pipeline
finance.yahoo.com - March 10 at 1:34 PM |
 | Complix Signs Global Drug Discovery and Development Agreement with I-Mab to Develop Cell Penetrating Alphabodies against Two Intracellular Immuno-oncology Targets
feeds.benzinga.com - March 10 at 8:28 AM |
| I-Mab to Report Financial Results for the Full Year 2020 and Provide Corporate Update on March 29, 2021
finance.yahoo.com - March 3 at 9:26 AM |
| Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-Mab Has Priced
finance.yahoo.com - February 9 at 9:49 AM |
| Proposed Registered Secondary Public Offering of American Depositary Shares by Certain Pre-IPO Shareholders of I-Mab
finance.yahoo.com - February 5 at 7:33 PM |
| I-Mab Announces Multiple Clinical Advancements of Its Differentiated CD73 Antibody Uliledlimab in China and the U.S.
finance.yahoo.com - February 5 at 9:24 AM |
| I-Mab Announces First Patient Dosed in Phase 2 Clinical Trial of TJ107 in Glioblastoma Multiforme in China
finance.yahoo.com - February 4 at 12:19 PM |
 | MorphoSys AG: MorphoSys and I-Mab Announce First Patient Dosed in U.S. Phase 1 Study of MOR210/TJ210 in Patients with Advanced Cancer
finanznachrichten.de - January 25 at 7:44 PM |
| I-Mab Announces Upcoming Participation at January Conferences
finance.yahoo.com - December 23 at 1:17 PM |
| I-Mab's (NASDAQ:IMAB) Intrinsic Value Is Potentially 23% Below Its Share Price
finance.yahoo.com - December 21 at 12:26 PM |
| I-Mab Added to Nasdaq Biotechnology Index
finance.yahoo.com - December 14 at 9:00 AM |
| Is IMAB A Good Stock To Buy Now?
finance.yahoo.com - December 11 at 3:15 PM |
| Week In Review: CANbridge Closes $43 Million E Round For Rare Disease Drugs
seekingalpha.com - December 6 at 4:12 PM |
| I-Mab Files Shelf Registration Statement for PIPE Investors
finance.yahoo.com - December 1 at 4:37 PM |
| I-Mab Appoints Leading Immunology and Hematology Experts to Its Scientific Advisory Board
finance.yahoo.com - December 1 at 8:31 AM |
| I-Mab's C5aR antibody TJ210/MOR210 shows strong scientific rationale as potential treatment for cancers
seekingalpha.com - November 11 at 9:16 AM |
